Strategic Acquisitions, New Drug Applications, Licensing Agreements, and Financial Results - Research Report on Horizon Pharma,

   Strategic Acquisitions, New Drug Applications, Licensing Agreements, and
 Financial Results - Research Report on Horizon Pharma, NPS Pharmaceuticals,
                       Spherix, Evoke Pharma, and POZEN

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 22, 2013

NEW YORK, November 22, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Horizon
Pharma, Inc. (NASDAQ: HZNP), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Spherix
Inc. (NASDAQ: SPEX), Evoke Pharma, Inc. (NASDAQ: EVOK), and POZEN Inc.
(NASDAQ: POZN). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Horizon Pharma, Inc. Research Report

On November 19, 2013, Horizon Pharma Inc. (Horizon) announced that it has
entered into an agreement to acquire the U.S. rights to VIMOVO
(naproxen/esomeprazole magnesium) delayed-release tablets from AstraZeneca AB.
According to the Company, this agreement further expands Horizon's focus on
key primary care physician targets in the U.S. Horizon informed that VIMOVO
is approved in the U.S. to relieve the signs and symptoms of osteoarthritis,
rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of
stomach ulcers in patients at risk of developing stomach ulcers from treatment
with NSAIDs. "The acquisition of VIMOVO is a major step forward in our
strategy to leverage our business model and maximize our commercial
infrastructure and we expect it to create significant value for our
shareholders," stated Timothy P. Walbert, Chairman, President and CEO of
Horizon. "We anticipate that this transaction will significantly increase our
revenues and accelerate the Company to profitable operations." The Full
Research Report on Horizon Pharma, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/05ea_HZNP

--

NPS Pharmaceuticals, Inc. Research Report

On November 13, 2013, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals)
announced that its Supplemental New Drug Application for Gattex® (teduglutide
[rDNA origin]) for injection has been accepted for review by the Food and Drug
Administration. In the US, Gattex is indicated for the treatment of adult
patients with Short Bowel Syndrome who are dependent on parenteral support.
"We are pleased that the FDA has accepted our sNDA for review," said Roger
Garceau, MD, FAAP, Executive Vice President and Chief Medical Officer of NPS
Pharmaceuticals. "The data from STEPS 2 we're proposing to include in the
label show that patients on Gattex treatment beyond one year continue to
achieve clinically meaningful reductions in parenteral support requirements,
with some achieving complete independence." The Full Research Report on NPS
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/441a_NPSP

--

Spherix Inc. Research Report

On November 19, 2013, Spherix Inc. (Spherix) announced that its wholly owned
subsidiary, CompuFill LLC, has entered into a settlement and license agreement
with a leading technology company. This is the first settlement and license
agreement for the CompuFill portfolio since Spherix acquired North South
Holdings LLC in September 2013. The Company informed that the ongoing
infringement enforcement continues as Spherix's model of patent monetization
grows in both scope and size. Anthony Hayes, Spherix CEO, stated, "The value
of having this suite of patents cannot be emphasized enough. Our team of
patent monetization experts brought this opportunity to Spherix only a few
short months ago and we have already started generating revenue. This is a
great example of how Spherix continues working to drive value for our
investors." The Full Research Report on Spherix Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/94a2_SPEX

--

Evoke Pharma, Inc. Research Report

On November 13, 2013, Evoke Pharma Inc. (Evoke Pharma) reported its Q3 2013
financial results with net loss of $0.5 million, or $0.41 per share,
relatively in line with the net loss reported in Q3 2012. R&D expenses totaled
$79,000 compared to $337,000 in Q3 2012. According to the Company, the
year-over-year decrease was primarily related to the decline in clinical
development-related costs as a larger portion of the labor cost was allocated
to general and administrative in 2013 as the Company prepared for its initial
public offering. On September 24, 2013, Evoke priced its initial public
offering of 2.1 million shares of common stock at $12.00 per share. Dave
Gonyer, R.Ph., President and CEO, stated, "With the net proceeds of our
initial public offering, we are well capitalized to move forward with the
planned Phase 3 trial for EVK-001, a metoclopramide nasal spray for the relief
of symptoms associated with acute and recurrent gastroparesis in women with
diabetes mellitus." The Full Research Report on Evoke Pharma, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/9af3_EVOK

--

POZEN Inc. Research Report

On November 6, 2013, POZEN Inc. (POZEN) reported its Q3 2013 financial results
with revenue of $2.6 million compared to $0.9 million in Q3 2012. Operating
expenses for the quarter totaled $7.4 million, compared to $6.7 million for Q3
2012. POZEN stated that the increase in operating expenses was primarily a
result of one-time costs associated with the PA8140/PA32540 agreement with
Sanofi US totaling $1.6 million. The Company reported a net loss of $4.8
million or $0.16 loss per share during the quarter, compared to a net loss of
$5.7 million or $0.19 per share in Q3 2012. The Full Research Report on POZEN
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/f226_POZN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.